Iibka Tooska ah ee Warshada Shiinaha CAS 1006376-62-0(1R,2R)-2-(3,4-difluorophenyl) cyclopropane carboxaMide kaydka iibka kulul

Ticagrelor waa daawada afka laga qaato ee antiplatelet, magaceeda summeedka Ameerika waa Brilinta, magaceeda summada Yurubna waa Brilique. Ticagrelor waa platelet adenosine diphosphate (ADP) antagonist reseptor ah oo la beddeli karo oo loogu talagalay in laga ilaaliyo platelets inay isku dhegaan oo ay sameeyaan xinjiro dhiig oo u horseedi kara wadne xanuun iyo istaroog. Dalka Mareykanka, ticagrelor waxaa markii ugu horreysay ansixiyay FDA bishii Luulyo 2011 si loogu daweeyo bukaannada qaangaarka ah ee qaba xanuunka wadnaha ee degdega ah (ACS). Xogta caafimaadku waxay muujinaysaa in ticagrelor uu si aad ah uga waxtar badan yahay clopidogrel si loo yareeyo dhimashada wadnaha iyo xididdada ugu yaraan 12 bilood ka dib dhacdo ACS ah. Intaa waxaa dheer, ticagrelorChemicalbook ayaa sidoo kale hoos u dhigay dhacdooyinka stent thrombosis (ST) ee bukaanada helay stent si loogu daweeyo ACS. Bishii Juun 2020, AstraZeneca waxay ku dhawaaqday in Maamulka Cunnada iyo Dawooyinka ee Mareykanka (FDA) ay ansixiyeen daawada xinjirowga lidka ku ah Brilinta (ticagrelor) si loogu isticmaalo bukaannada qaba cudurka halbowlayaasha khatarta sare leh (CAD) si loo yareeyo khatarta wadne qabadka koowaad. ama khatarta istaroogga. Bishii Noofambar 2020, AstraZeneca waxay ku dhawaaqday in Maamulka Cuntada iyo Dawooyinka ee Mareykanka (FDA) ay ansixiyeen tilmaame cusub oo loogu talagalay daawada xinjirowga lidka ku ah Brilinta (ticagrelor), oo ay weheliso aspirin, oo loogu talagalay daaweynta ischemia ba'an. Bukaannada qaba istaroogga dhiigbaxa ama khatarta sare ee ischemic weerar (TIA), waxay yaraynaysaa khatarta istaroogga xiga.